Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05284643 · ClinicalTrials.gov registry record · NA
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
A NA study of Recurrent Glioblastoma, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT05284643: Recruiting NA study of Recurrent Glioblastoma, sponsored by University of Miami.
NCT05284643 is a NA study of Recurrent Glioblastoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 96 participants, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05284643, a NA study of Recurrent Glioblastoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Proton radiotherapy and bevacizumab (Avastin) are used to minimize the possible side effects of this approach.
Primary Outcome
The percentage of participants for whom sMRI-guided therapy is successful will be reported as the percentage of participants who show no significant residual tumor after protocol therapy.
Conditions Studied
Interventions
- DRUG Bevacizumab
- RADIATION Intensity Modulated Proton Therapy (IMPT)
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2029-09-30 |
| Phase | NA |
What NCT05284643 shows while recruiting
NCT05284643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05284643 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05284643 about?
NCT05284643 is a clinical study titled "Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma". The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in at...
What is the current status of trial NCT05284643?
This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2022-09-30. Estimated completion is 2029-09-30.
What conditions does trial NCT05284643 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT05284643?
The interventions under investigation include: Bevacizumab (DRUG), Intensity Modulated Proton Therapy (IMPT) (RADIATION).
Who is sponsoring clinical trial NCT05284643?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05284643 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05284643's enrollment target sits among peer trials
96 10th of 62 higher than 53 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · NA
-
Mathematical Model-Adapted Radiation In Glioblastoma
COMPLETED · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI